Brose MS. Next generation biomarkers and targeting of thyroid and salivary gland cancers. ASCO 2022 Education Session;Abstract.

Brose MS et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 2022;128(24):4203-12. Abstract

Cabanillas ME et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol 2017;35(29):3315-21. Abstract

Demetri GD et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 2022;28(7):1302-12. Abstract

Florou V et al. Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib. J Natl Compr Canc Netw 2021;19(5):478-82. Abstract

Hyman D et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). AACR 2019;Abstract CT127.

Waguespack SG et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 2022;186(6):631-43. Abstract

Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383(9):825-35. Abstract